CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 168 enrolled
Drug / intervention
Technolas® TENEO 317 Model 2device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04111757
NCT04111757N/ACompleted
CompareCT.gov

A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism

Bausch & Lomb Incorporated·interventional·Posted Oct 1, 2019·Updated Jun 14, 2024

In Brief

A clinical study evaluating Technolas® TENEO 317 Model 2 for Myopia and Myopic Astigmatism. Completed, enrolled 168 participants across 10 sites.

Detailed Summary

The primary objective of this study is to collect safety and effectiveness data for the Technolas Teneo 317 Model 2 excimer laser for LASIK correction in participants with myopia and myopic astigmatism.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopia, Myopic Astigmatism
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedOct 1, 2019
Enrollment StartJul 25, 2019
Primary CompletionAug 6, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 6.8 years ago

Interventions

Technolas® TENEO 317 Model 2device

LASIK eye surgery